Targovax ASA (TA50) Stock Price & Analysis

TA50 Stock Chart & Stats

€0.98-€0.04(-3.82%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: EUR 0.98 - EUR 1.01
52-Week Range: EUR 0.07 - EUR 1.33
Previous Close: EUR 1.02
Volume: 100
Average Volume (3M): 0
Market Cap: EUR 288.14M
Enterprise Value: EUR 1.01B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -32.47
Next Earnings: Feb 18, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Targovax ASA News

Circio Showcases High-Specificity circVec Advances at ESGCT, Sharpening Gene Therapy Focus

An announcement from Targovax ASA ( ($GB:0RIS) ) is now available. Circio Holding ASA, listed on the Oslo Stock Exchange, develops circular RNA-based gene expression systems intended to enhance the

4d agoTA50 0RIS

Circio Aligns Board Compensation with Shareholders Through RSU Issuance

An announcement from Targovax ASA ( ($GB:0RIS) ) is now available. Circio Holding ASA, a biotechnology company specializing in advanced circular RNA expression systems for gene and cell therapies, is

1M agoTA50 0RIS

Circio scraps follow-on share issue after market undercuts placement price

An update from Targovax ASA ( ($GB:0RIS) ) is now available. Circio Holding ASA has cancelled a planned subsequent share offering of up to 16,865,000 new shares, which was originally

1M agoTA50 0RIS

Circio Holding Registers Share Capital Increase After NOK 200 Million Private Placement

Targovax ASA ( ($GB:0RIS) ) has provided an update. Circio Holding ASA has completed a private placement of 16,865,000 new shares, raising approximately NOK 200 million to support its operations

1M agoTA50 0RIS

Circio Raises NOK 200 Million to Accelerate Circular RNA Platform Development

The latest announcement is out from Targovax ASA ( ($GB:0RIS) ). Circio Holding ASA has raised approximately NOK 200 million in a private placement through the issuance of 16,865,000 new

1M agoTA50 0RIS

Circio raises NOK 200m to fast-track in vivo CAR-T ambitions

Targovax ASA ( ($GB:0RIS) ) has shared an update. Circio Holding ASA has raised approximately NOK 200 million in a private placement directed at Nordic and international investors, issuing 16,865,000

1M agoTA50 0RIS

Circio boosts circVec gene therapy data and secures funding runway to 2030

The latest update is out from Targovax ASA ( ($GB:0RIS) ). Circio Holding ASA reported that new preclinical data show its circVec circular RNA technology delivering up to 60-fold higher

2M agoTA50 0RIS

Circio and Full Circles join forces on non-viral in vivo cell therapy platform

Targovax ASA ( ($GB:0RIS) ) just unveiled an announcement. Circio Holding ASA and Full Circles Therapeutics have entered a research collaboration to combine Circio’s circVec circular RNA expression platform with

2M agoTA50 0RIS

Circio bolsters board as it advances circular RNA gene therapy platform

Targovax ASA ( ($GB:0RIS) ) has issued an announcement. Circio Holding ASA has strengthened its board of directors as it enters a new development phase focused on advancing a lead

2M agoTA50 0RIS

Circio to Present H1 2026 Results and New circVec Gene Therapy Data

Targovax ASA ( ($GB:0RIS) ) has issued an announcement. Circio Holding ASA will publish its first half 2026 report on 31 August and follow up with a live webcast from

2M agoTA50 0RIS

TA50 FAQ

What was Targovax ASA’s price range in the past 12 months?

Targovax ASA lowest stock price was €0.07 and its highest was €1.33 in the past 12 months.

What is Targovax ASA’s market cap?

Targovax ASA’s market cap is €288.14M.

When is Targovax ASA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Targovax ASA’s earnings last quarter?

Targovax ASA released its earnings results on Aug 31, 2026. The company reported -€0.019 earnings per share for the quarter.

Is Targovax ASA overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Targovax ASA pay dividends?

Targovax ASA does not currently pay dividends.

What is Targovax ASA’s EPS estimate?

Targovax ASA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Targovax ASA have?

Targovax ASA has 291,492,920 shares outstanding.

What happened to Targovax ASA’s price movement after its last earnings report?

Targovax ASA reported an EPS of -€0.019 in its last earnings report. Following the earnings report the stock price went down -2.156%.

Which hedge fund is a major shareholder of Targovax ASA?

Currently, no hedge funds are holding shares in DE:TA50

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Targovax ASA

Circio Holding ASA, a biotechnology firm based in Oslo, Norway, and founded in 2010, specializes in the development of advanced circular RNA and immunotherapy treatments. Among its key innovations is TG01, a cancer vaccine aimed at specific driver mutations, which is currently progressing through three clinical trials for indications including multiple myeloma, pancreatic cancer, and lung cancer. The company also pioneers the circVec circRNA vector platform, an adaptable genetic module designed to facilitate the creation of diverse functional circular RNAs within human cells. This circVec platform is further supported by a collaborative agreement with Certest Biotec, S.L., focusing on its formulation. Formerly known as Targovax ASA, the company officially rebranded to Circio Holding ASA in May 2023.

Targovax ASA (TA50) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	8	4	10
Technical Analysis	4	4	2
Moving Averages	4	0	8

Technical Analysis >

Ownership Overview

0.10% Mutual Funds
99.68% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

TA50 Stock Chart & Stats

Targovax ASA News

Circio Showcases High-Specificity circVec Advances at ESGCT, Sharpening Gene Therapy Focus

Circio Aligns Board Compensation with Shareholders Through RSU Issuance

Circio scraps follow-on share issue after market undercuts placement price

Circio Holding Registers Share Capital Increase After NOK 200 Million Private Placement

Circio Raises NOK 200 Million to Accelerate Circular RNA Platform Development

Circio raises NOK 200m to fast-track in vivo CAR-T ambitions

Circio boosts circVec gene therapy data and secures funding runway to 2030

Circio and Full Circles join forces on non-viral in vivo cell therapy platform

Circio bolsters board as it advances circular RNA gene therapy platform

Circio to Present H1 2026 Results and New circVec Gene Therapy Data

TA50 FAQ

Company Description

Targovax ASA

Targovax ASA (TA50) Earnings & Revenues

Technical Analysis

Overall Consensus

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium